Phase I trial of the combination of the multikinase inhibitor nintedanib plus letrozole: A window of opportunity trial in adjuvant hormone-receptor positive breast cancer (HRPBC).

被引：0
|
作者：
Rodriguez, Laura Medina
Guerra, Juan Antonio
Malon, Diego
Laura, Rodriguez
Colomer, Ramon
Quintela-Fandino, Miguel
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS615
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS615
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase I trial of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in hormone-receptor positive metastatic breast cancer.
    Lebowitz, PF
    Eng-Wong, J
    Balis, F
    Widemann, B
    Jayaprakash, N
    Gantz, S
    Chow, C
    Merino, M
    Zujewski, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 38S - 38S
  • [2] Intermittent letrozole as adjuvant treatment in postmenopausal hormone-receptor positive early breast cancer patients
    Balduzzi, A.
    Bagnardi, V.
    Volpe, S.
    Cancello, G.
    Iorfida, M.
    Dellapasqua, S.
    Sandri, M.
    Goldhirsch, A.
    Colleoni, M.
    CANCER RESEARCH, 2013, 73
  • [3] Comparison of the efficacy of adjuvant letrozole and anastrozole in hormone-receptor positive postmenopausal breast cancer patients.
    Sendur, Mehmet Ali Nahit
    Aksoy, Sercan
    Altundag, Kadri
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer
    Yuan, Yuan
    Lee, Jin Sun
    Yost, Susan E.
    Frankel, Paul H.
    Ruel, Christopher
    Egelston, Colt A.
    Guo, Weihua
    Padam, Simran
    Tang, Aileen
    Martinez, Norma
    Schmolze, Daniel
    Presant, Cary
    Ebrahimi, Behnam
    Yeon, Christina
    Sedrak, Mina
    Patel, Niki
    Portnow, Jana
    Lee, Peter
    Mortimer, Joanne
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 11 - 20
  • [5] The HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole plus zoledronic acid
    Perrone, F.
    De laurentiis, M.
    de Placido, S.
    Orditura, M.
    Cinieri, S.
    Riccardi, F.
    Ribecco, A. S.
    Putzu, C.
    Del Mastro, L.
    Rossi, E.
    Daniele, B.
    Mosconi, A. M.
    Di Rella, F.
    Landi, G.
    Nuzzo, F.
    Pacilio, C.
    Lauria, R.
    Arenare, L.
    Piccirillo, M. C.
    Gallo, C.
    ANNALS OF ONCOLOGY, 2018, 29 : 704 - 704
  • [6] Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR plus ) metastatic breast cancer (MBC).
    Tan, Antoinette R.
    Wong, Serena Tsan-Lai
    Warren, Robert D.
    Eng-Wong, Jennifer
    Liu, Minetta C.
    Zelnak, Amelia Bruce
    Lin, Yong
    Shih, Weichung
    Ganesan, Shridar
    Grana, Generosa
    Isaacs, Claudine
    Toppmeyer, Deborah
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
    Jisun Kim
    Woosung Lim
    Eun-Kyu Kim
    Min-Kyoon Kim
    Nam-Sun Paik
    Sang-Seol Jeong
    Jung-han Yoon
    Chan Heun Park
    Sei Hyun Ahn
    Lee Su Kim
    Sehwan Han
    Seok Jin Nam
    Han-Sung Kang
    Seung Il Kim
    Young Bum Yoo
    Joon Jeong
    Tae Hyun Kim
    Taewoo Kang
    Sung-Won Kim
    Yongsik Jung
    Jeong Eon Lee
    Ku Sang Kim
    Jong-Han Yu
    Byung Joo Chae
    So-Youn Jung
    Eunyoung Kang
    Su Yun Choi
    Hyeong-Gon Moon
    Dong-Young Noh
    Wonshik Han
    BMC Cancer, 14
  • [8] Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
    Kim, Jisun
    Lim, Woosung
    Kim, Eun-Kyu
    Kim, Min-Kyoon
    Paik, Nam-Sun
    Jeong, Sang-Seol
    Yoon, Jung-han
    Park, Chan Heun
    Ahn, Sei Hyun
    Kim, Lee Su
    Han, Sehwan
    Nam, Seok Jin
    Kang, Han-Sung
    Kim, Seung Il
    Yoo, Young Bum
    Jeong, Joon
    Kim, Tae Hyun
    Kang, Taewoo
    Kim, Sung-Won
    Jung, Yongsik
    Lee, Jeong Eon
    Kim, Ku Sang
    Yu, Jong-Han
    Chae, Byung Joo
    Jung, So-Youn
    Kang, Eunyoung
    Choi, Su Yun
    Moon, Hyeong-Gon
    Noh, Dong-Young
    Han, Wonshik
    BMC CANCER, 2014, 14
  • [9] Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial
    Azim, Hamdy A.
    Saleh, Mariam A.
    Eldin, Passant Essam
    Abdelhafeez, Ahmed A. M.
    Hassan, Mohamed
    Kassem, Loay
    JOURNAL OF CHEMOTHERAPY, 2025, 37 (02) : 159 - 167
  • [10] A phase II trial of letrozole in combination with bevacizumab, an anti-VEGF antibody, in patients with hormone receptor-positive metastatic breast cancer
    Traina, TA
    Dickler, MN
    Caravelli, JF
    Yeh, BM
    Brogi, E
    Panageas, K
    Flores, SA
    Norton, L
    Park, J
    Hudis, C
    Rugo, H
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S93 - S94
12345